We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.97%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$815M
AUM Growth
+$105M
Cap. Flow
+$27.8M
Cap. Flow %
3.41%
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
36
Reduced
33
Closed
18

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$22.9M
2
SDGR icon
Schrodinger
SDGR
+$16.6M
3
FTRE icon
Fortrea Holdings
FTRE
+$14.8M
4
OSCR icon
Oscar Health
OSCR
+$11.4M
5
HCA icon
HCA Healthcare
HCA
+$10.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
BSX icon
Boston Scientific
BSX
+$14.6M
3
KROS icon
Keros Therapeutics
KROS
+$10.8M
4
MTD icon
Mettler-Toledo International
MTD
+$9.1M
5
HUM icon
Humana
HUM
+$8.28M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Industrials 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
101
BridgeBio Pharma
BBIO
$16.4B
– –
-100,734
Closed -$4.07M
BDTX icon
102
Black Diamond Therapeutics
BDTX
$121M
– –
-253,717
Closed -$713K
BMY icon
103
Bristol-Myers Squibb
BMY
$130B
– –
-100,000
Closed -$5.13M
COGT icon
104
Cogent Biosciences
COGT
$6.76B
– –
-96,837
Closed -$569K
CRSP icon
105
PUT
CRISPR Therapeutics
CRSP
$5.22B
– –
-50,000
Closed -$3.13M
GPCR icon
106
Structure Therapeutics
GPCR
$3.83B
– –
-38,678
Closed -$1.58M
HUM icon
107
Humana
HUM
$46.7B
– –
-18,081
Closed -$8.28M
IMUX icon
108
Immunic
IMUX
$217M
– –
-10,226
Closed -$153K
LNTH icon
109
Lantheus
LNTH
$6.57B
– –
-80,000
Closed -$4.96M
LQDA icon
110
Liquidia Corp
LQDA
$7.01B
– –
-101,767
Closed -$1.22M
MTD icon
111
Mettler-Toledo International
MTD
$28.8B
– –
-7,500
Closed -$9.1M
NEO icon
112
NeoGenomics
NEO
$2.11B
– –
-237,762
Closed -$3.85M
SUPN icon
113
Supernus Pharmaceuticals
SUPN
$2.78B
– –
-119,417
Closed -$3.46M
TNGX icon
114
Tango Therapeutics
TNGX
$4.31B
– –
-65,679
Closed -$650K
ASLN
115
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-13,832
Closed -$57.8K
AMAM
116
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-87,678
Closed -$1.25M
SLGC
117
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-890,099
Closed -$2.25M
1 2 3 4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Parkman Healthcare Partners held 117 positions worth $815M, up 15% from $710M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners deployed $27.8M of net new capital in Q1 2024, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was Eli Lilly: 32,117 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $14.6M trimmed.

  • Parkman Healthcare Partners's largest Q1 2024 buy was Eli Lilly: 32,117 shares worth $25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q1 2024, an estimated $16.6M increase.
  • Parkman Healthcare Partners's biggest Q1 2024 reduction was Boston Scientific, cutting an estimated $14.6M.
  • Parkman Healthcare Partners fully exited Amgen in Q1 2024, selling an estimated $17.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $815M portfolio in Q1 2024.
  • Parkman Healthcare Partners opened 28 new positions and closed 18 in Q1 2024.
  • Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $815M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.